North American Scientific
This article was originally published in The Gray Sheet
Executive Summary
Firm completes stock-swap acquisition of radiopharmaceutical developer Theseus Oct. 16. The price tag of roughly $18.5 mil. includes about $10.5 mil. of Theseus' debt. Ongoing European and U.S. clinical trials for Theseus' Apomate imaging agent are being funded by NAS (1"The Gray Sheet" Nov. 30, 1998, p. 23)
You may also be interested in...
North American Scientific/Theseus Medical
Funding for Phase II trials of Theseus' Apomate and Leukomate radiopharmaceutical agent for nuclear medicine imaging will come from North American Scientific in the form of a $3.5 mil. advance payment related to its planned $3 mil. acquisition of the company, a letter of intent for which is announced Nov. 24. A 30-patient Phase I trial of Apomate, a Technetium-99-m-labeled imaging agent, is complete. Data from preclinical studies showed that the agent effectively binds to apoptosis-specific cell markers of responsive tumor cells within one to two hours of chemotherapy
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.